Biotechnology
Commented by André Will-Laudien on November 27th, 2025 | 07:55 CET
Black Friday: DAX explodes, and biotech is back in vogue: Watch out for 100% gains at Bayer, Vidac Pharma, and Novo Nordisk
The stock market has managed to break out of its consolidation phase, and the upward trend is continuing toward the end of the year. There are signs of hope for the Leverkusen-based pharmaceutical company Bayer, and Vidac Pharma is moving into the primary segment of the Düsseldorf over-the-counter market. The well-known Novo Nordisk, whose share price has been destroyed, is experiencing its fourth sell-off in three months. Some analysts are now turning positive. Investors should now be aware that prices in the biotech sector have fallen so low that even minor news items are enough to cause prices to skyrocket. Especially during the year-end portfolio adjustments, prices often reach absurd levels. We help you navigate the thicket of valuations.
Read
Commented by André Will-Laudien on November 18th, 2025 | 07:25 CET
Nvidia figures ahead, AI correction looming? Doubling alternatives include Planethic Group, Bayer, Eli Lilly, and Novo Nordisk
It does not always have to be Nvidia! If the current level of risk on the NASDAQ feels a bit too high, investors should take a look at some European gems. There may be less AI involved here, but people still work for people. This is particularly interesting as Elon Musk aims to equip the core zone of human interaction with humanoid robots, from cooking together in the kitchen to family life, which could receive "digital offspring" as early as 2027. Because the planet will soon face food and water shortages due to permanent overheating, we are taking a closer look at completely analog topics such as alternative nutrition and the prevention of obesity. This is certainly too boring for the disciples of the digital apocalypse, but it offers plenty of charm for non-digital investors.
Read
Commented by Carsten Mainitz on November 18th, 2025 | 07:10 CET
Takeover fever! LAURION Mineral Exploration, Evotec, and Mutares are tempting investors to get on board!
M&A – mergers and acquisitions - remain powerful performance drivers for shareholders of potential takeover targets. But companies that acquire others also benefit from increased growth, access to new markets and technologies, and cost synergies. According to a recent study by Bain & Company, the majority of M&A activity in the current year, amounting to around USD 265 billion, has taken place in the energy and commodities sectors. In healthcare and life sciences, deals with a volume of USD 107 billion were recorded. So who could the next takeover candidates be?
Read
Commented by Armin Schulz on November 18th, 2025 | 07:05 CET
Patents, potential, takeover candidate? Making money with less risk: The secret of BioNxt Solutions
In the high-risk world of biotechnology, the path from the laboratory to an approved drug is often an ordeal. Canadian company BioNxt Solutions may have found the key to a less painful path. Instead of developing expensive and uncertain new active ingredients, the Company refines proven drugs with innovative administration technology. The past few months have brought a remarkable series of successes that not only confirm the technology but also significantly increase the strategic value of the Company. For investors, this could be a rare opportunity.
Read
Commented by Fabian Lorenz on November 17th, 2025 | 07:10 CET
Out of BioNTech? Into Evotec and Vidac shares? What is going on with Johnson & Johnson?
Big news in biotech: Pfizer is selling its entire stake in German biotech champion BioNTech. Should investors consider doing the same? Meanwhile, Vidac Pharma is providing more and more reasons for a price explosion. The Company is developing a novel cancer therapy and has received approval to begin phase 2 clinical trials in Germany. It is also reportedly in talks with Johnson & Johnson. Might the pharmaceutical giant even make a move? Evotec, on the other hand, has recently sent mixed signals. Another milestone payment is ringing the cash register, and insider transactions are drawing attention. Yet the stock is trading at a multi-year low.
Read
Commented by Armin Schulz on November 14th, 2025 | 07:20 CET
Cancer will become curable - and these stocks could then be priceless: Evotec, Vidac Pharma, and Bayer
Cancer remains one of the greatest medical challenges of our time - but at the same time, it is creating business opportunities worth billions. The oncology market is literally exploding with annual growth of 10.8%, driven by aging societies and groundbreaking therapeutic approaches. Artificial intelligence is revolutionizing diagnostics, personalized medicine is making previously incurable tumors treatable, and digital platforms are dramatically accelerating drug development. While patients benefit from tailored treatments, investors sense big business opportunities. Today, we analyze Evotec, Vidac Pharma, and Bayer for their positioning in this future market.
Read
Commented by André Will-Laudien on November 13th, 2025 | 07:20 CET
Record stock market! And the momentum continues with Palantir, D-Wave, Gerresheimer, and NetraMark
Artificial intelligence (AI) is fundamentally changing drug development by analyzing vast amounts of data in record time and controlling clinical trials more precisely. Advanced systems identify promising drug candidates and predict therapeutic success with impressive accuracy. Companies such as NetraMark are already successfully using these technologies to accelerate development processes. At the same time, the well-known AI stars Palantir and D-Wave are driving the next wave of innovation as pacemakers in data analysis and quantum computing, recording extraordinary share price gains. The German Gerresheimer Group is also increasingly integrating AI-supported solutions into the manufacture of pharmaceutical packaging and medical technology. For investors, this represents a pool of opportunities, but the choice remains difficult!
Read
Commented by Stefan Feulner on November 11th, 2025 | 07:00 CET
Vistra, NetraMark, Snap – AI stocks with potential
The bull market of recent months has given way to disillusionment, as AI stocks were sold off last week despite strong quarterly results. Is hedge fund manager Michael Burry, famous from "The Big Short," right again? According to the latest 13F filing from Scion Asset Management, Burry holds put options on Nvidia and Palantir with a total value of around USD 1.1 billion and is betting on sharply falling prices. He points to the exceptionally high valuations of these companies as the reason for his pessimism. However, not all stocks in the field of artificial intelligence are overpriced. Some promising names with significant upside potential can still be found among the second-tier players.
Read
Commented by Nico Popp on November 10th, 2025 | 07:10 CET
Patient well-being as the key to returns: Oramed Pharmaceuticals, Roche, BioNxt
Higher, faster, further – constant progress is not only important in sports. The economy and science are also all about continuous innovation and improvement. Biotechnology combines both areas. We show how new, patient-centered approaches can capture market share and also create added value for investors. To this end, we take a look at the Swiss pharmaceutical company Roche, show how the Israeli biotech company Oramed has learned from setbacks, and how BioNxt Solutions is securing promising patents with innovative dosage forms.
Read
Commented by Fabian Lorenz on November 7th, 2025 | 07:00 CET
Takeover battle between Novo Nordisk and Pfizer! Is BioNxt Solutions the next target?
Who will acquire Metsera? That is currently the subject of dispute between Novo Nordisk and Pfizer. Both pharma giants are seeking access to a new generation of metabolic therapies through the acquisition - treatments that have the potential to transform the billion-dollar market for obesity and diabetes care. Novo Nordisk views Metsera's drug pipeline as a complement to its GLP-1-based preparations, while Pfizer is trying to finally gain a foothold in the market after several setbacks. The takeover battle illustrates that big pharma companies are willing to dig deep into their pockets for innovations. This makes BioNxt Solutions a potential takeover candidate. The Company is not only working on innovations in the field of multiple sclerosis and obesity, but on an entire platform technology.
Read